Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 20, 2021Journal of Pharmacy TechnologyOpen Access

Safety and Efficacy of Apixaban Use in Peritoneal Dialysis: A Review of the Literature

View Full Paper
Ask AI
Bookmark
Share

Why the study?

To evaluate the safety and efficacy of apixaban for treating nonvalvular atrial fibrillation or venous thromboembolism in patients receiving peritoneal dialysis.

Does apixaban improve safety and efficacy compared to standard therapy in patients receiving peritoneal dialysis for nonvalvular atrial fibrillation or venous thromboembolism?

Comparison

Apixaban vs standard therapy

Design

Literature review of retrospective studies

Authors

AAArmaghan AmaniCFCaitlin M. FellersAEAntoinette Eyebe

Discussion

Loading...

Member takes

Implication

Apixaban use in peritoneal dialysis lacks robust data; leaves open optimal dosing and safety for AF or VTE.

Structured PICO

Does apixaban improve safety and efficacy compared to standard therapy in patients receiving peritoneal dialysis for nonvalvular atrial fibrillation or venous thromboembolism?

P
Population
Patients with end-stage renal disease (ESRD) receiving peritoneal dialysis (PD) with nonvalvular atrial fibrillation or venous thromboembolism (based on 4 retrospective studies)
I
Intervention
Apixaban
C
Comparator
Standard therapy (warfarin)
O
Outcome
Safety and efficacy clinical outcomes

Apixaban may be a safe and effective alternative to warfarin in patients on peritoneal dialysis, though data specific to this population remains extremely limited.

Limitations

  • Very limited number of subjects receiving peritoneal dialysis
  • Outcomes did not differentiate between patients receiving peritoneal dialysis or not
  • Included studies were retrospective

Cite This Study

Amani et al. (2021) studied this question.

synapsesocial.com/papers/6a7564bc96d04a2f43f5959chttps://doi.org/10.1177/8755122520988728
View Full Paper
Ask AI
Bookmark
Share